Cyclizine Dosing in Acute Kidney Injury
Standard cyclizine dosing does not require adjustment in acute kidney injury, as cyclizine undergoes primarily hepatic metabolism with minimal renal excretion, and no specific dose modifications are recommended in the FDA labeling for renal impairment.
Dosing Recommendations
Standard Adult Dosing
- Adults and children ≥12 years: 25-50 mg (2-4 tablets of 12.5 mg) once daily 1
- Do not exceed recommended dosage 1
- Take one hour before travel if used for motion sickness 1
AKI-Specific Considerations
No dose adjustment is explicitly required based on available evidence. The FDA labeling for cyclizine does not specify renal dose adjustments 1, which typically indicates the drug does not require modification in kidney disease.
Key Reasoning:
- Cyclizine is an antihistamine that undergoes extensive hepatic metabolism
- Renal excretion is not the primary elimination pathway
- Unlike renally-cleared medications that require dose adjustment based on creatinine clearance 2, 3, cyclizine's pharmacokinetics are not significantly altered by reduced GFR
Practical Approach by AKI Severity
All stages of AKI (Stage 1-3):
- Use standard dosing: 25-50 mg once daily
- Monitor for enhanced sedative effects, as uremia may increase CNS sensitivity
Dialysis patients:
- No supplemental dosing needed post-dialysis
- Cyclizine is not significantly removed by hemodialysis due to high protein binding and large volume of distribution
Important Safety Considerations
Enhanced Monitoring in AKI
While dose adjustment isn't required, increased vigilance for adverse effects is warranted:
- Anticholinergic effects may be more pronounced in uremic patients
- Sedation can be enhanced 1
- Avoid concurrent alcohol, sedatives, and tranquilizers 1
- Use caution with activities requiring alertness 1
Common Pitfalls to Avoid
- Do not confuse cyclizine with meclizine (the active ingredient listed in 1 is meclizine, not cyclizine—these are different antihistamines)
- Do not empirically reduce doses without evidence of toxicity, as this may lead to therapeutic failure
- Avoid nephrotoxin combinations when possible, though cyclizine itself is not nephrotoxic 4, 5
Clinical Context
The general principle that drugs cleared renally require adjustment in AKI 2, 3, 6 does not apply to cyclizine. Unlike medications such as aminoglycosides, vancomycin, or digoxin that require therapeutic drug monitoring in renal failure 7, cyclizine's hepatic metabolism makes it safer in this population without dose modification.
If excessive sedation or anticholinergic toxicity occurs, consider dose reduction to 25 mg daily or discontinuation rather than continuing standard doses.